This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.

Start Date01 Mar 2025

Sponsor / Collaborator

Inova Health Care Services

NCT06564207

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study for the Long Term Evaluation of Fostamatinib for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome (ARDS)

This study is designed to evaluate the safety and efficacy of fostamatinib in hospitalized adult participants with acute respiratory distress syndrome (ARDS).

Start Date01 Feb 2025

Sponsor / Collaborator

Inova Health Care Services

[+2]

NCT06746428

/ Not yet recruitingNot ApplicableIIT

ACTIVATE: A Pilot Randomized Activity Coaching Trial to Increase Vitality and Energy During Post-operative Pelvic Radiation Therapy for Endometrial Cancer

Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.

Start Date01 Feb 2025

Sponsor / Collaborator

Inova Health Care Services

100 Clinical Results associated with Inova Health Care Services

0 Patents (Medical) associated with Inova Health Care Services

2,417

Literatures (Medical) associated with Inova Health Care Services

01 Feb 2025·Journal of Vascular Surgery Cases, Innovations and Techniques

Aortic aneurysm management results through one year with a conformable neck sealing endograft and preemptive sac embolization with shape memory polymer devices

Article

Author: Li, Jihui ; Mukherjee, Dipankar ; Spinosa, David

Management of abdominal aortic aneurysm includes reducing the incidence of endoleaks and promoting sac regression. Sac embolization has been shown to promote regression but alone may not adequately address type II endoleak risk. We present three cases with challenging anatomy and follow-up data through 12 months after treatment. Patients were treated with endografts, and shape memory polymer embolization plugs were used to embolize the residual lumen volume outside of the endograft during the procedure. Follow-up imaging indicates that this procedure was used successfully in these patients. None of the patients developed sac expansion or developed type II endoleaks.

01 Jan 2025·Modern Pathology

Early Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian Neoplasms

Article

Author: Zhu, Jiarun ; Shih, Ie-Ming ; Song, Qianqian ; Chui, M. Herman ; Chui, M Herman ; Vang, Russell ; Wang, Yeh ; Wang, Tian-Li ; Jiao, Yuchen ; Wang, Brant

The current paradigm implicates a fallopian tube precursor as the origin of most ovarian high-grade serous carcinomas (HGSCs). However, a rare subset of HGSCs develop via a distinct pathway from low-grade serous ovarian neoplasms (namely, serous borderline tumors and low-grade serous carcinoma). This alternate pathway for the development of HGSC and other poorly differentiated carcinomas of the ovary is not well understood. To elucidate the molecular pathogenesis and evolutionary trajectory of histologic transformation of low-grade serous neoplasms, we performed whole exome sequencing on microdissected low-grade and higher-grade components from 7 cases of serous borderline tumor or low-grade serous carcinoma associated with a synchronous or metachronous indeterminate/high-grade carcinoma. In most cases, there were relatively few somatic mutations shared between matched low-grade and higher-grade tumors compared with private mutations specific to each component (ie, phylogenetic trees with short trunks and long branches). Truncal mutations, present across all tumor samples from a given patient, included known drivers of low-grade serous neoplasms: KRAS (G12D, n = 4), BRAF (G469A, n = 1), NF2 (n = 1), and USP9X (n = 1). Transformation to HGSC was associated with a TP53 mutation with bi-allelic inactivation in 3 cases, all with severe nuclear atypia, and associated with genome-wide copy number alterations and allelic imbalances. TP53-wildtype tumors comprised a morphologic spectrum, which included indeterminate-grade serous carcinomas with moderate nuclear atypia and high mitotic activity, although lacking extensive chromosomal instability (n = 2) and poorly differentiated carcinomas (n = 2, including a high-grade Mullerian carcinoma and an undifferentiated carcinoma with sarcomatoid features). In summary, synchronous and metachronous low-grade serous neoplasms and higher-grade carcinomas are clonally related. Early genetic divergence, most evident in cases with TP53 mutations, suggests that high-grade transformation may be a relatively early molecular event.

01 Jan 2025·The American Journal of Human Genetics

Discovery of a DNA methylation profile in individuals with Sifrim-Hitz-Weiss syndrome

Article

Author: Gorman, Kathleen ; Gallant, Emily ; McCann, Cathleen ; Sidlow, Richard ; McConkey, Haley ; Ghoumid, Jamal ; O'Shea, Jessica ; Sallevelt, Suzanne ; Hauser, Natalie ; Marin, Victor ; Prasad, Chitra ; Bouman, Arjan ; Wentzensen, Ingrid M ; Hannibal, Mark ; Menke, Leonie A ; Lichtenstein, Yael ; Smol, Thomas ; Weiss, Karin ; Relator, Raissa ; Patel, Chirag ; Balci, Tugce B ; Karimi, Karim ; Motta, Jamie ; Lancaster, Emily ; Reilly, Jack ; Miranda, Valancy ; Tedder, Matthew L ; Louie, Raymond J ; Clarkson, Katie ; Valenzuela Palafoll, Irene ; Barkan, Tali ; Keren, Boris ; Maria-Noelia, Seco Moro ; Diaz de Bustamante, Aranzazú ; Raskin, Salmo ; Poirsier, Celine ; Drazba, Katy ; Marom, Daphna ; Turnpenny, Peter D ; Levy, Michael A ; Kerkhof, Jennifer ; Morrison, Jennifer ; Campeau, Philippe M ; Cohen, Lior ; Symonds, Joseph D ; Sadikovic, Bekim ; Colin, Estelle ; Rankin, Julia

Pathogenic heterozygous variants in CHD4 cause Sifrim-Hitz-Weiss syndrome, a neurodevelopmental disorder associated with brain anomalies, heart defects, macrocephaly, hypogonadism, and additional features with variable expressivity. Most individuals have non-recurrent missense variants, complicating variant interpretation. A few were reported with truncating variants, and their role in disease is unclear. DNA methylation episignatures have emerged as highly accurate diagnostic biomarkers in a growing number of rare diseases. We aimed to study evidence for the existence of a CHD4-related DNA methylation episignature. We collected blood DNA samples and/or clinical information from 39 individuals with CHD4 variants, including missense and truncating variants. Genomic DNA methylation analysis was performed on 28 samples. We identified a sensitive and specific DNA methylation episignature in samples with pathogenic missense variants within the ATPase/helicase domain. The same episignature was observed in a family with variable expressivity, a de novo variant near the PHD domain, variants of uncertain significance within the ATPase/helicase domain, and a sample with compound heterozygous variants. DNA methylation data revealed higher percentages of shared probes with BAFopathies, CHD8, and the terminal ADNP variants encoding a protein known to form the ChAHP complex with CHD4. Truncating variants, as well as a sample with a recurrent pathogenic missense variant, exhibited DNA methylation profiles distinct from the ATPase/helicase domain episignature. These DNA methylation differences, together with the distinct clinical features observed in those individuals, provide preliminary evidence for clinical and molecular sub-types in the CHD4-related disorder.

100 Deals associated with Inova Health Care Services

100 Translational Medicine associated with Inova Health Care Services

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Jan 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Inova Health Care Services

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 24 Jan 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing